Business
Results of in-vitro clinical trial published
Results of in-vitro clinical trial published.
About this update from Venture Life Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3520F\n Venture Life Group PLC\n 16 November 2020\n \n \n \n \n 16 November 2020\n \n \n \n \n \n VENTURE LIFE GROUP PLC\n \n \n (\"Venture Life\" \"VLG\" or the \"Company\")\n \n \n Cardiff University's published in-vitro study reports two CPC-based mouthwashes completely eradicate SARS-CoV-2 (COVID-19) within a 30 second exposure\n \n Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announced on 24 August 2020 its involvement in a UK-led clinical trial, with one of its key oral care brands containing the powerful Cetylpyridinium Chloride (\"CPC\") technology, on those affected with COVID-19. This independent, multi-centre clinical study, led by Professor David Thomas at Cardiff University, investigates the possibility that using over-the-counter mouthwashes containing CPC could help to reduce the viral load of COVID-19 in the mouth. \n Today, the Company provides an update on the recently published[1]in-vitro results from a separate, independent laboratory study undertaken at Cardiff University by Dr Richard Stanton and his colleagues.\n In their published in-vitro[2] study, scientists at Cardiff University concluded that Venture Life's two CPC based mouthwashes eradicated the SARS-CoV-2 (COVID-19) virus completely (>5log reduction, equivalent to 99.999%) within a 30 second exposure. The virus was supplied by Public Health England, unlike other similar studies reported in the media, which have not used the relevant COVID-19 virus, but a related strain of it.\n Cardiff University went on to state that the 'exact formulation is also important'. Whilst the CPC technology in Venture Life's mouthwash proved highly effective in the in-vitro study, they also tested a third mouthwash, which also contained both CPC and another ingredient, yet this proved ineffective. Their conclusion was that active ingredients in mouthwashes were not, on their own, enough to rely on, but rather it was the construct of the mouthwash formulations that was the critical determinant of a successful outcome. The Board considers the composition of Venture Life's CPC-based mouthwashes to be unique.\n The Company looks forward to concluding the human (in-vivo) clinical study in partnership with Cardiff University and will update the market with the...